The CIN4 Chromosomal Instability qPCR Classifier Defines Tumor Aneuploidy and Stratifies Outcome in Grade 2 Breast Cancer
Szász, Attila Marcell
Eklund, Aron C.
MetadataShow full item record
CitationSzász, Attila Marcell, Qiyuan Li, Aron C. Eklund, Zsófia Sztupinszki, Andrew Rowan, Anna-Mária Tőkés, Borbála Székely, et al. 2013. The CIN4 chromosomal instability qPCR classifier defines tumor aneuploidy and stratifies outcome in grade 2 breast cancer. PLoS ONE 8(2): e56707.
AbstractPurpose Quantifying chromosomal instability (CIN) has both prognostic and predictive clinical utility in breast cancer. In order to establish a robust and clinically applicable gene expression-based measure of CIN, we assessed the ability of four qPCR quantified genes selected from the 70-gene Chromosomal Instability (CIN70) expression signature to stratify outcome in patients with grade 2 breast cancer. Methods: AURKA, FOXM1, TOP2A and TPX2 (CIN4), were selected from the CIN70 signature due to their high level of correlation with histological grade and mean CIN70 signature expression in silico. We assessed the ability of CIN4 to stratify outcome in an independent cohort of patients diagnosed between 1999 and 2002. 185 formalin-fixed, paraffin-embedded (FFPE) samples were included in the qPCR measurement of CIN4 expression. In parallel, ploidy status of tumors was assessed by flow cytometry. We investigated whether the categorical CIN4 score derived from the CIN4 signature was correlated with recurrence-free survival (RFS) and ploidy status in this cohort. Results: We observed a significant association of tumor proliferation, defined by Ki67 and mitotic index (MI), with both CIN4 expression and aneuploidy. The CIN4 score stratified grade 2 carcinomas into good and poor prognostic cohorts (mean RFS: 83.8±4.9 and 69.4±8.2 months, respectively, p = 0.016) and its predictive power was confirmed by multivariate analysis outperforming MI and Ki67 expression. Conclusions: The first clinically applicable qPCR derived measure of tumor aneuploidy from FFPE tissue, stratifies grade 2 tumors into good and poor prognosis groups.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:10622924
- HMS Scholarly Articles 
Showing items related by title, author, creator and subject.
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas Johnatty, Sharon E.; Beesley, Jonathan; Gao, Bo; Chen, Xiaoqing; Lu, Yi; Law, Matthew H.; Henderson, Michelle J.; Russell, Amanda J.; Hedditch, Ellen L.; Emmanuel, Catherine; Fereday, Sian; Webb, Penelope M.; Goode, Ellen L.; Vierkant, Robert A.; Fridley, Brooke L.; Cunningham, Julie M; Fasching, Peter A.; Beckmann, Matthias W.; Ekici, Arif B.; Hogdall, Estrid; Kjaer, Susanne K.; Jensen, Allan; Hogdall, Claus; Brown, Robert; Paul, Jim; Lambrechts, Sandrina; Despierre, Evelyn; Vergote, Ignace; Lester, Jenny; Karlan, Beth Y.; Heitz, Florian; du Bois, Andreas; Harter, Philipp; Schwaab, Ira; Bean, Yukie; Pejovic, Tanja; Levine, Douglas A.; Goodman, Marc T.; Camey, Michael E.; Thompson, Pamela J.; Lurie, Galina; Shildkraut, Joellen; Berchuck, Andrew; Terry, Kathryn Lynne; Cramer, Daniel William; Norris, Murray D.; Haber, Michelle; MacGregor, Stuart; deFazio, Anna; Chenevix-Trench, Georgia (Elsevier BV, 2013)Objective ABCB1 encodes the multi-drug efflux pump P-glycoprotein (P-gp) and has been implicated in multi-drug resistance. We comprehensively evaluated this gene and flanking regions for an association with clinical ...
Prior-Cancer Diagnosis in Men with Nonmetastatic Prostate Cancer and the Risk of Prostate-Cancer-Specific and All-Cause Mortality Mirabeau-Beale, Kristina; Chen, Ming-Hui; D'Amico, Anthony V. (Hindawi Publishing Corporation, 2014)Purpose. We evaluated the impact a prior cancer diagnosis had on the risk of prostate-cancer-specific mortality (PCSM) and all-cause mortality (ACM) in men with PC. Methods:. Using the SEER data registry, 166,104 men (median ...
Prostate Cancer (PCa) Risk Variants and Risk of Fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium Shui, Irene M.; Lindström, Sara; Kibel, Adam S.; Berndt, Sonja I.; Campa, Daniele; Gerke, Travis; Penney, Kathryn L.; Albanes, Demetrius; Berg, Christine; Bueno-de-Mesquita, H. Bas; Chanock, Stephen; Crawford, E. David; Diver, W. Ryan; Gapstur, Susan M.; Gaziano, J. Michael; Giles, Graham G.; Henderson, Brian; Hoover, Robert; Johansson, Mattias; Marchand, Loic Le; Ma, Jing; Navarro, Carmen; Overvad, Kim; Schumacher, Fredrick R.; Severi, Gianluca; Siddiq, Afshan; Stampfer, Meir; Stevens, Victoria L.; Travis, Ruth C.; Trichopoulos, Dimitrios; Vineis, Paolo; Mucci, Lorelei A.; Yeager, Meredith; Giovannucci, Edward; Kraft, Peter (Elsevier, 2014)Background: Screening and diagnosis of prostate cancer (PCa) is hampered by an inability to predict who has the potential to develop fatal disease and who has indolent cancer. Studies have identified multiple genetic risk ...